Weighing the social costs of weight-loss drugs

A wildly popular class of drugs called GLP-1 agonists—which includes Ozempic, Wegovy, Mounjaro, and Zepbound—are revolutionizing the treatment of obesity. One in eight adults has tried a GLP-1 drug for weight loss or to manage their diabetes, and a tidal wave of research is revealing that these medications may also help with a range of health issues, from lowering the risk of heart disease and certain cancers to treating sleep apnea and substance use disorders. “These drugs are making a big difference because of how effective they are,” says Angela Godwin Beoku-Betts, a clinical assistant professor at the NYU Rory Read More